Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)

Line Uhrenholt, Annette Schlemmer, Ellen Margrethe Hauge, Robin Christensen, Lene Dreyer, Maria E. Suarez-Almazor, Salome Kristensen

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)'. Together they form a unique fingerprint.

Medicine & Life Sciences